The effect of intravenous Calcium gluconate on the prevention of Ovarian Hyperstimulation Syndrome. (A randomized clinical trial).

Oral Cabergoline and intravenous Calcium have the potential to prevent Ovarian Hyperstimulation Syndrome (OHSS) in assisted reproductive technology by regulating the activity of the Vascular Endothelial Growth Factor (VEGF) receptor. The purpose of this study was to examine the effect of Cabergoline with intravenous Calcium versus oral Cabergoline alone on the overall rate of OHSS. This study is a randomized clinical trial which was carried out in Milad Infertility Center affiliated with Mashhad University of Medical Sciences, Mashhad, Iran between April 2016 and January 2018. A total of 192 patients were randomly assigned into two groups. The control group received oral Cabergoline and the intervention group received Calcium gluconate in addition to Cabergoline. A total rate of OHSS, moderate and severe OHSS were measured in both groups. The demographic characteristics of the participants and the types of drugs used showed homogeneity between the intervention and control groups (p>.05). Furthermore, there was no significant difference between the two groups in terms of the number of the follicle, oocytes obtained, metaphase II oocytes, the number of embryos, and the rate of fertilization. Regarding the incidence of OHSS, 26.2% of participants in the control group experienced OHSS, while the occurrence rate was 15.7% in the intervention group (P =.401). The incidence of severe OHSS in the control group and intervention group was 7.1% and 3.6%, respectively. Intravenous injection of Calcium gluconate can be effective in preventing Ovarian Hyperstimulation Syndrome.

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest There are no conflicts of interest